For many people with hemophilia around the world, access to care and treatment can be a considerable daily challenge. Through the expanded WFH Humanitarian Aid Program, increased multi-year donations now means it is possible for people with bleeding disorders in the developing world to have continued access to treatment for emergency situations, acute bleeds, corrective surgeries, and also prophylaxis for young children.
In 2017 alone, over 16,000 patients received treatment through the WFH Humanitarian Aid Program. This exceeds the total number of patients receiving treatment through the program from 1996 to 2016. This is as a direct result of the significant level of donations provided by Bioverativ, a Sanofi company, and Sobi, with the visionary commitment of 500 million international units of clotting factor concentrates treatment products, over 5 years, along with their substantial financial support for the operational needs of this program.
Through this contribution to the WFH Humanitarian Aid Program, local healthcare professionals reported that more than 15,000 people with hemophilia, in 40 countries, were treated in 2017. Significant outcomes occurred during the past year: 1,192 people have been put on prophylactic treatment since the start of the expansion of the program; over 40,500 acute bleeds were treated last year; and more than 700 surgeries were completed in 2017.
“Not only is the sheer volume of surgeries a big step forward for the facility, but the variety of performed surgeries is also important, because it has allowed doctors to broaden their experience, become better at their jobs, and consequently, provide better care for patients,” said Vikash Goyal, President of the Haemophilia Federation of India.
As the cost of treatment is prohibitively expensive for the majority of those affected with a bleeding disorder, donations of this magnitude means a complete shift in how patients are now treated in developing countries. The reality is that limited access to diagnosis and treatment in many developing countries means that people with severe hemophilia in these areas often do not survive to adulthood. The demonstrated results of the WFH Humanitarian Aid Program are leading to a change in this reality.
“With treatment now available through the WFH Humanitarian Aid Program for those most in need in these countries, healthcare professionals and patient organizations can rely on these donations to treat new patients and conduct outreach programs with more confidence,” explained Assad Haffar, WFH Director of Humanitarian Aid.
To support healthcare providers that received donated treatment, the WFH Humanitarian Aid Program also provides a range of integrated care development training programs to ensure the local infrastructure and medical expertise are available to optimize and appropriately use donated products.
Continued demonstrable leadership will give hope to those who had no realistic option for treatment before. We will keep working with all our global partners to come together to further strengthen the success of the WFH Humanitarian Aid Program.
About the World Federation of Hemophilia
For over 50 years, the World Federation of Hemophilia (WFH), an international not-for-profit organization, has worked to improve the lives of people with hemophilia and other inherited bleeding disorders. Established in 1963, it is a global network of patient organizations in 134 countries and has official recognition from the World Health Organization. Visit WFH online at www.wfh.org.
WFH USA advances the global mission of the World Federation of Hemophilia in the United States.
About the WFH Humanitarian Aid Program
For many developing countries, humanitarian aid donations are often the only source of treatment products for people with hemophilia and other bleeding disorders. An increasing number of collaborators within the global bleeding disorders community have accepted the challenge of providing a sustainable and predictable supply of donated products. The visionary contribution from Bioverativ, a Sanofi company, and Sobi to the WFH Humanitarian Aid Program translates into 500 million IUs over five years (2015-2020). Bioverativ and Sobi also make ongoing substantial financial contributions to support the logistics of product delivery and training of providers and patients in humanitarian aid countries. Furthermore, the eight-year commitment (2014-2021) from Grifols totaling 200 million IUs, along with a ten-year commitment (2009-2018) from CSL Behring for a total of 22 million IUs, and the three-year agreement (2017-2019) with Green Cross for 6 million IUs, allows for a more predictable and sustainable flow of humanitarian aid donations to the global community.